AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
New HIV/AIDS study findings reported from K.G. Saskova and co-authors
November 3rd, 2008
According to a study from Prague, Czech Republic, "Lopinavir (LPV) is a second-generation HIV protease inhibitor (PI) designed to overcome resistance development in patients undergoing long-term antiviral therapy. The mutation of isoleucine at position 47 of the HIV protease (PR) to alanine is associated with a high level of resistance to LPV." "In this study, we show that recombinant PR containing a single I47A substitution has the inhibition constant (K-i) value for lopinavir by two orders of magnitude higher than for the wild-type PR. The addition of the I47A substitution to the background of a multiply mutated PR species from an AIDS patient showed a...
Source: AIDS Weekly (2008-11-03)
|
